Innospec's Q3 Earnings Beat Estimates on Chemicals Strength

Zacks
Zacks에서 열기
Innospec's Q3 Earnings Beat Estimates on Chemicals Strength

Innospec Inc. IOSP reported third-quarter 2026 adjusted earnings of $1.29 per share, up 15.2% from $1.12 a year ago. The figure topped the Zacks Consensus Estimate of $1.26 by 2.4%. Growth in Performance Chemicals and Oilfield Services operating income supported the results.

Revenues rose 7.2% year over year to $473.6 million but missed the consensus estimate of $479.2 million by 1.1%. All three businesses posted sales gains, with Oilfield Services recording the fastest growth at 13.4%.

Innospec Inc. Price, Consensus and EPS Surprise

Innospec Inc. Price, Consensus and EPS Surprise

Innospec Inc. price-consensus-eps-surprise-chart | Innospec Inc. Quote

IOSP's Performance Chemicals Margin Improvement

Performance Chemicals revenues increased 5.7% year over year to $180.5 million. A favorable 12% contribution from pricing and product mix more than offset a 5% reduction in volumes and a 1% negative foreign currency impact. The sales mix helped cushion softer volumes.

The segment's gross margin expanded 3.7 percentage points to 18.8%. Operating income surged 83.7% to $16.9 million from $9.2 million. Management expects efficiency upgrades at its North Carolina plant to be commissioned by year-end, improving capacity, productivity and yields across personal care and other products.

Innospec's Fuel Specialties Delivers Steady Growth

Fuel Specialties sales climbed 5.1% year over year to $180.7 million. Volume growth of 3% combined with a 2% favorable price and product mix contribution. The segment continued to generate growth from both shipment activity and pricing.

Gross margin contracted 0.5 percentage points to 35.1%, although management noted that margins remained within its target range. Operating income edged up 0.8% to $35.6 million from $35.3 million. The relatively modest profit increase contrasted with stronger gains in the other two businesses, reflecting the segment's broadly steady performance.

IOSP's Oilfield Services Sales and Profit Advance

Oilfield Services revenues grew 13.4% year over year to $112.4 million. The business benefited from the recent expansion of its drag-reducing agent (DRA) plant, which supported higher operating income and improved operating margins.

Operating income advanced 39.6% to $6.7 million from $4.8 million. However, gross margin declined 1.8 percentage points to 28.2% due to a weaker sales mix. Sequential performance fell short of management's expectations because of continued activity delays in the legacy Middle East business and elevated raw material costs.

IOSP's Cash Flow and Debt-Free Balance Sheet

Cash provided by operating activities declined to $17.4 million from $39.1 million a year earlier. Capital spending was $15.6 million in the quarter, leaving limited cash generation after capital expenditures. 

Management remains focused on improving working capital efficiency to support stronger operating cash flow.

Innospec ended the third quarter with $251.9 million in cash and cash equivalents and no debt.

Innospec's Outlook Centers on Operating Gains

Management expects Performance Chemicals to benefit from the North Carolina upgrades as utilization of added capacity improves and new-product development progresses. The company sees opportunities for further growth and margin improvement over the coming quarters, particularly in this business.

For Oilfield Services, management expects improvements in areas affected by delayed Middle East activity and elevated raw material costs to support sequential operating income growth in the fourth quarter. Fuel Specialties is expected to maintain consistent performance. Innospec continues to evaluate organic investment, acquisitions, dividends and share repurchases as uses of its balance-sheet flexibility.

IOSP’s Price Performance

IOSP’s shares have increased 6.9% over a year compared with the 18.4% growth recorded by the Zacks Chemicals Diversified industry.

Zacks Investment Research
Image Source: Zacks Investment Research

IOSP’s Zacks Rank & Other Chemical Releases

IOSP currently carries a Zacks Rank #5 (Strong Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. 

Quaker Chemical Corporation KWR reported third-quarter adjusted earnings of $2.39 per share, beating the Zacks Consensus Estimate of $2.16 by 10.6%. KWR expects fourth-quarter revenues and adjusted EBITDA to improve year over year but decline sequentially from third-quarter levels. 

Huntsman Corporation HUN reported third-quarter adjusted earnings of 4 cents per share. This compares with a loss of 3 cents in the year-ago quarter. Earnings missed the Zacks Consensus Estimate of 7 cents per share by 42.9%. HUN anticipates improved earnings and cash flow to reduce net debt leverage to approximately four times by year-end, supported by higher volumes, cost reductions and disciplined execution.

Olin Corporation OLN logged third-quarter adjusted earnings of 14 cents per share, beating the Zacks Consensus Estimate of 10 cents by 40%. For the fourth quarter of 2026, OLN expects adjusted EBITDA between $80 million and $100 million. 

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Free: See Our Top Stock And 4 Runners Up

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Innospec Inc. (IOSP): Free Stock Analysis Report
 
Huntsman Corporation (HUN): Free Stock Analysis Report
 
Quaker Houghton (KWR): Free Stock Analysis Report
 
Olin Corporation (OLN): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research